7.2 Temporary Mechanical Circulatory Support: IABP, Impella & TandemHeart

In cardiogenic shock, profound primary myocardial dysfunction triggers a self-reinforcing downward spiral: falling cardiac output lowers mean arterial pressure and coronary perfusion pressure, inducing further myocardial ischemia. Compensatory systemic vasoconstriction raises afterload, while elevated ventricular filling pressures increase wall tension and myocardial oxygen consumption ($M\text{VO}_2$). Temporary mechanical circulatory support (tMCS) devices are deployed to break this cycle by uncoupling systemic perfusion from native ventricular stroke work, decreasing intracardiac filling pressures, and augmenting coronary and vital organ blood flow.

---

1. Hemodynamic Objectives & Pressure-Volume Loop Dynamics

The fundamental physiological objectives of tMCS include:

1. Unloading the Ventricle: Reducing left ventricular end-diastolic volume (LVEDV) and pressure (LVEDP), which lowers wall stress according to Laplace's Law ($\sigma = \frac{P \cdot r}{2h}$). Lower wall stress relieves subendocardial microvascular compression and diminishes myocardial oxygen demand ($M\text{VO}_2$).
2. Augmenting Systemic Perfusion: Increasing mean arterial pressure, effective cardiac output, and cardiac power output ($\text{CPO} = \frac{\text{MAP} \times \text{CO}}{451}$), thereby reversing end-organ hypoperfusion and lactic acidosis.
3. Elevating Coronary Perfusion Pressure: Enhancing the diastolic pressure gradient across the coronary bed ($\text{CPP} = \text{Aortic Diastolic Pressure} - \text{LVEDP}$).

Pressure-Volume (PV) Loop Dynamics under Mechanical Circulatory Support:

Pressure
   ^
   |        Native LV (Shock)        IABP Counterpulsation       Impella Microaxial Unloading
   |       ┌────────────────┐         ┌───────────────┐               ┌────────┐
   |       │                │         │               │               │        │
   |       │  High Afterload│         │ Lower Presyst │               │        │ Continuous
   |       │   High LVEDP   │         │ Reduced Work  │               │ Narrow │ Aspiration
   |       │                │         │               │               │ Loop   │ Shifts PV Loop
   |       └────────────────┘         └───────────────┘               └────────┘ Down & Left
   +──────────────────────────>       ─────────────────>              ─────────>
               Volume                      Volume                       Volume

---

2. Intra-Aortic Balloon Pump (IABP)

The Intra-Aortic Balloon Pump is the most widely utilized and historically established tMCS device. It consists of a dual-lumen balloon catheter (balloon volumes $30\text{--}50\text{ mL}$) inserted retrogradely through the common femoral artery into the descending thoracic aorta. Its tip is positioned $1\text{ to }2\text{ cm}$ distal to the origin of the left subclavian artery, terminating proximally above the celiac and renal arterial take-offs.

The Physiology of Diastolic Counterpulsation

The IABP relies on shuttle gas (helium, chosen for low molecular weight and low viscosity, enabling rapid displacement) synchronized with the cardiac cycle:

1. Diastolic Inflation (Diastolic Augmentation):
   • Timing: Rapid inflation occurs precisely at the dicrotic notch on the arterial waveform, signaling aortic valve closure and the onset of diastole.
   • Hemodynamic Mechanism: The expanding balloon abruptly displaces $30\text{--}50\text{ mL}$ of blood retrogradely into the ascending aorta and aortic root, generating a prominent diastolic augmentation peak that substantially elevates coronary and cerebral perfusion pressure.
2. Systolic Deflation (Presystolic Afterload Reduction):
   • Timing: Rapid deflation occurs immediately prior to ventricular systole, during isovolumetric contraction (corresponding to the peak of the R-wave on surface ECG or just prior to the arterial systolic upstroke).
   • Hemodynamic Mechanism: Sudden evacuation of helium creates a transient vacuum or suction effect in the aorta. Aortic end-diastolic pressure drops precipitously, markedly reducing the impedance (afterload) against which the left ventricle must eject. Isovolumetric contraction time is shortened, stroke work is diminished, and LV myocardial oxygen consumption drops by $10\%\text{ to }15\%$.

Waveform Interpretation & Critical Timing Errors

Synchronizing IABP inflation and deflation is essential. Inaccurate timing compromises hemodynamic efficacy and can induce catastrophic afterload spikes:

IABP Arterial Waveform Timing Comparison:

Pressure
   ^               Normal Counterpulsation                      Late Deflation Error
   |              [ Diastolic Augmentation ]                 [ Prolonged Balloon Inflation ]
   |                       /\                                           /\ 
   |         /\           /  \                         /\              /  \  /\ [ Impeded Native
   |        /  \         /    \                       /  \            /    \/  \  Ejection ]
   |       /    \       /      \                     /    \          /          \
   |      /      \_____/        \                   /      \________/            \
   |     /  Systole   Dicrotic   \ Assisted        /  Systole   Dicrotic       Assisted
   |    /              Notch      \ Systole       /              Notch         Systole
   +───┴───────────────────────────┴──────────>  ┴──────────────────────────────┴───────> Time

1. Early Inflation: Balloon inflates before the dicrotic notch, encroaching on active systole. The aortic valve is forced shut prematurely, elevating LV afterload, worsening mitral regurgitation, and reducing stroke volume.
2. Late Inflation: Inflation occurs well after the dicrotic notch. The diastolic augmentation peak is truncated and rounded, resulting in sub-optimal coronary perfusion augmentation.
3. Early Deflation: Balloon deflates prematurely during mid-to-late diastole. The diastolic augmentation wave decays rapidly, retrograde coronary blood steal may occur, and the afterload-reducing vacuum effect is lost prior to ventricular contraction.
4. Late Deflation: Balloon remains inflated when ventricular systole begins. The native LV is forced to eject against an occluded aorta, producing a massive spike in presystolic afterload, severe elevation in LV wall stress, and reduction in cardiac output.

Evidence: The IABP-SHOCK II Trial & Guideline Reclassifications

For decades, IABP counterpulsation was considered mandatory first-line therapy for acute myocardial infarction complicated by cardiogenic shock (AMI-CS). However, clinical practice changed radically following the landmark IABP-SHOCK II Trial (Thiele et al., NEJM 2012):

• Study Design: 600 patients with AMI complicated by cardiogenic shock undergoing early revascularization (primarily primary PCI) were randomized to routine IABP insertion versus medical therapy without IABP.
• Primary Outcome: 30-day all-cause mortality was identical: $39.7\%$ in the IABP group versus $41.3\%$ in the control group (relative risk 0.96; $p = 0.69$).
• Long-Term Follow-up: Subsequent 12-month and 6-year follow-up analyses confirmed no difference in all-cause mortality, recurrent infarction, stroke, or repeat revascularization.
• Guideline Revisions: In response to IABP-SHOCK II, both ACC/AHA and European Society of Cardiology (ESC) guidelines downgraded routine IABP in AMI-CS to Class III (No Benefit / Routine Use Not Recommended).
• Remaining Valid Indications: IABP retains a Class IIa recommendation (ESC 2023) as a bridge in mechanical complications of acute myocardial infarction, specifically acute mitral regurgitation due to papillary muscle rupture and ventricular septal defect (VSD), serving as an afterload-reducing stabilizer prior to emergency surgical repair.

Contraindications to IABP

• Moderate-to-Severe Aortic Regurgitation: Diastolic balloon inflation forces high-pressure blood retrogradely across the incompetent aortic valve into the LV cavity, causing acute, massive LV overdistension, pulmonary edema, and electromechanical dissociation.
• Aortic Dissection or Severe Thoracic/Abdominal Aneurysm: Risk of intimomedial tearing, false lumen expansion, or catastrophic aortic rupture.
• Severe Peripheral Artery Disease or Femoral Bypass Grafting.

---

3. Impella Microaxial Transvalvular Assist Devices

The Impella system represents an active, continuous-flow microaxial pump mounted on a catheter platform. Positioned retrogradely across the aortic valve using fluoroscopic and transesophageal echocardiographic guidance, its inlet rests within the LV cavity (mid-cavity, $4\text{--}4.5\text{ cm}$ below the aortic valve, pointed toward the LV apex), while its outlet sits in the ascending aorta.

Impella Microaxial Transvalvular Blood Flow Architecture:

         [ Ascending Aorta ]
                  ▲
                  │ Blood Expelled at Outlet (P-Level Continuous Flow)
            [ Motor Unit ]
                  ▲
         =================== [ Aortic Valve Plane ]
                  ▲
            [ Cannula ]
                  ▲
                  │ Blood Aspirated at Inlet
       [ Left Ventricular Cavity ]

Mechanism of Action & Hemodynamics

• The internal Archimedes screw motor spins at speeds up to 45,000 RPM, drawing blood continuously from the LV cavity and discharging it into the ascending aorta.
• Direct Mechanical LV Unloading: Unlike IABP (which requires native ventricular ejection to generate stroke volume), Impella provides direct, active forward output independent of myocardial contraction. It directly evacuates blood from the LV, reducing LVEDV, LVEDP, and LV wall stress, while simultaneously elevating mean arterial pressure and cardiac output.
• PV Loop Transformation: Impella shifts the left ventricular pressure-volume loop leftward and downward, transforming the rectangular or trapezoidal loop into a narrow, triangular contour with an extinguished or shortened isovolumetric phase, substantially shrinking the pressure-volume area (PVA) and drastically reducing myocardial oxygen consumption.

Impella Device Models & Specifications

1. Impella 2.5: 12 Fr microaxial pump delivering up to $2.5\text{ L/min}$ flow; inserted percutaneously via a 13 Fr femoral sheath.
2. Impella CP (Cardiac Power): 14 Fr pump delivering up to $3.5\text{--}4.0\text{ L/min}$ flow; inserted percutaneously via a 14 Fr peel-away femoral sheath. Standard platform for high-risk PCI and early cardiogenic shock.
3. Impella 5.0 / 5.5 with SmartAssist: Surgical microaxial pumps delivering up to $5.0\text{ to }5.5\text{ L/min}$ of full circulatory support. Impella 5.5 is inserted via an axillary or subclavian cutdown through an end-to-side vascular graft, completely avoiding femoral access and permitting patient extubation, physical rehabilitation, and ambulation as a bridge to recovery or durable LVAD/transplantation.
4. Impella RP: Percutaneous microaxial pump designed for isolated right ventricular failure, aspirating blood from the inferior vena cava and discharging it into the main pulmonary artery across the tricuspid and pulmonic valves at flows up to $4.0\text{ L/min}$.

Clinical Management, Alarms & Complications

• Suction Alarms & Cannula Malposition: If the inlet cannula abuts the ventricular endocardium, papillary muscles, or interventricular septum, or if severe right ventricular failure or hypovolemia diminishes LV preload, the pump cavitates, triggering a "suction alarm". The console automatically down-regulates pump performance level (P-level). Management requires volume expansion, treatment of RV failure, or echocardiographic repositioning of the catheter.
• Mechanical Hemolysis: Extreme rotational shear stress across the high-speed microaxial impeller induces mechanical destruction of circulating erythrocytes. Monitored via serial plasma free hemoglobin ($> 40\text{--}50\text{ mg/dL}$), serum lactate dehydrogenase (LDH), and dark red/tea-colored urine (hemoglobinuria) that can induce acute tubular necrosis.
• Vascular Access Ischemia & Distal Perfusion: Large-bore (14 Fr) femoral sheaths can occlude the superficial or common femoral artery, particularly in patients with peripheral vascular disease, causing acute lower extremity ischemia. Distal perfusion monitoring (pulse oximetry on the great toe, continuous Doppler interrogation) is mandatory.
• Bleeding & Acquired von Willebrand Syndrome: High shear forces across the impeller cleave high-molecular-weight multimers of von Willebrand factor, causing acquired von Willebrand disease and severe mucosal or puncture-site bleeding.
• Aortic Valve Trauma & Ventricular Arrhythmias: Cannula contact with the aortic valve leaflets or subvalvular apparatus can induce chordal rupture, acute aortic insufficiency, or intractable ventricular tachycardia.
• Contraindications: Mechanical aortic valve prosthesis, severe aortic stenosis (impedes catheter crossing and risks calcific embolization), moderate-to-severe aortic regurgitation, and documented left ventricular thrombus (high risk of fatal systemic embolization).

Evidence: The DanGer Shock Trial

The DanGer Shock trial (Møller et al., NEJM 2024) randomized 360 patients (355 analyzed) with STEMI complicated by cardiogenic shock (lactate $\ge 2.5\text{ mmol/L}$, LVEF $< 45\%$; comatose out-of-hospital arrest and predominant RV shock excluded) to routine Impella CP plus standard care or standard care alone:

• Primary outcome: 180-day all-cause death 45.8% vs. 58.5% (hazard ratio 0.74, 95% CI 0.55-0.99; $p = 0.04$), an NNT of about 8.
• Harms: The composite of severe bleeding, limb ischemia, hemolysis, device failure, or worsening aortic regurgitation occurred in 24.0% vs. 6.2%, and renal replacement therapy was more frequent (41.9% vs. 26.7%).
• Guideline impact: The 2025 ACC/AHA/multisociety ACS guideline makes the microaxial flow pump a Class 2a option for selected patients with STEMI and severe or refractory cardiogenic shock, while routine IABP remains Class 3 (no benefit).

The result applies to a selected STEMI-CS population; it does not establish benefit for unselected cardiogenic shock, heart failure-related shock, or comatose arrest survivors.

SCAI SHOCK Stages

The Society for Cardiovascular Angiography and Interventions (SCAI) staging system (2019, updated 2022) grades shock severity and helps match escalation to risk:

Mortality rises steeply from stage C to E, and a modifier is added for cardiac arrest with coma.

---

4. TandemHeart: Left Atrial-to-Femoral Arterial Bypass

The TandemHeart is an extracorporeal continuous-flow centrifugal pump system that unloads the left heart by aspirating blood from the left atrium and returning it into the arterial system:

• Cannulation Architecture:
  • Venous Drainage Cannula ($21\text{ Fr}$): Inserted via the femoral vein, advanced through the inferior vena cava, and passed across the interatrial septum into the left atrium via fluoroscopic and transesophageal echocardiography (TEE)-guided transseptal puncture.
  • Arterial Reinfusion Cannula ($15\text{--}17\text{ Fr}$): Positioned in the contralateral common femoral artery, discharging blood into the abdominal and thoracic aorta.
• Hemodynamic Effects: Provides up to $3.5\text{--}4.0\text{ L/min}$ of systemic blood flow. By directly evacuating oxygenated blood from the left atrium, it effectively decompresses the left heart, reducing left atrial pressure, PCWP, LVEDP, and LV volume. Unlike Impella, TandemHeart does not cross the aortic valve or enter the LV cavity, making it safe in patients with aortic stenosis, severe aortic regurgitation, or left ventricular thrombus.
• Technical Challenges & Risks: Requires specialized interventional cardiology expertise for emergency transseptal puncture in an unstable patient. Potential catastrophic complications include left atrial or aortic root perforation with cardiac tamponade, cannula dislodgement into the right atrium (which converts the circuit into a massive right-to-left shunt producing severe refractory hypoxemia), and a persistent residual atrial septal defect (ASD) following decannulation.

---

5. Comprehensive MCS Devices Comparison Table